← Aura Biosciences, Inc. (AURA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Aura Biosciences, Inc. (AURA)
Biological Products, (No Diagnostic Substances) · market cap $627M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Aura Biosciences (AURA) is a small-cap ocular oncology biotech with 106 employees and a ~$705M market cap. Its lead asset, bel-sar, recently completed a Phase 3 trial in choroidal melanoma (June 2026), with a Phase 2 AU-011 readout in uveal melanoma expected around November 2026. The company carries $84.8M in cash against a burn rate implying roughly 8.5 months of runway, creating a near-term financing overhang.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
- 2026-11-30 (est.)Phase 2 · AU-011imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Bel-sar | Phase 3 | Choroidal Melanoma |
| Light-activated AU-011 | Phase 2 | Uveal Melanoma |
| AU-011 | Phase 2 | Eye Cancer |
Price & technical context
3-month
-22.0%
6-month
-9.9%
12-month
-2.3%
52-wk range
$4.97–$8.90
vs 50-day MA
-15.7%
vs 200-day MA
-9.0%
Realized vol
55.9%
Max drawdown
-58.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AURA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.